South Korea Immunoglobulin Market Forecast 2022-2028

The South Korea immunoglobulin market is predicted to project a CAGR of 8.11% during the estimated years. While the base year regarded for the market study is 2021, the forecast period is from 2022 to 2028. The main factors promoting the market growth of the country are the prevalence of different diseases and disorders due to weak immune systems as well as the increasing geriatric population.

MARKET INSIGHTS

Immunoglobulins entail antibodies that are naturally produced by the immune system of the body. They primarily help fight diseases and infections. The glycoprotein molecules are created by plasma cells and represent a vital component of the body's immune response. Immunoglobulins precisely recognize and bind to particular antigens, such as viruses and bacteria, while stimulating their obliteration.

According to statistics, the elderly population in South Korea equated to nearly 3.51 million males and 4.61 million females in 2020. This figure is set to rise and reach approximately 9.84 million females and 8.98 million males by the year 2060. Hence, the significant increase in the geriatric population is projected to heighten the incidence of various disorders and diseases on account of weak immune systems. This factor, subsequently, will boost the demand for immunoglobulin products for treatments. As a result, the aforementioned drivers are set to influence the immunoglobulin market growth in South Korea over the forecast period.

COMPETITIVE INSIGHTS

The top firms operating in the market include: Green Cross, ABL Bio, Celltrion, etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Product Code: 46405

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. COUNTRY SNAPSHOT
2.4. COUNTRY ANALYSIS
2.5. KEY GROWTH ENABLERS
2.6. KEY CHALLENGES

3. KEY ANALYTICS

3.1. IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
3.2. KEY MARKET TRENDS
3.3. PORTER'S FIVE FORCES ANALYSIS
- 3.3.1. BUYERS POWER
- 3.3.2. SUPPLIERS POWER
- 3.3.3. SUBSTITUTION
- 3.3.4. NEW ENTRANTS
- 3.3.5. INDUSTRY RIVALRY
3.4. OPPORTUNITY MATRIX
3.5. PESTLE ANALYSIS
3.6. KEY BUYING CRITERIA
- 3.6.1. SOURCE
- 3.6.2. APPLICATION
- 3.6.3. EPITOPE
- 3.6.4. VALIDATION

4. MARKET BY PRODUCT

4.1. IGG
4.2. IGA
4.3. IGM
4.4. IGE
4.5. IGD

5. MARKET BY MODE OF DELIVERY

5.1. INTRAVENOUS IMMUNOGLOBULIN
5.2. SUBCUTANEOUS IMMUNOGLOBULIN
5.3. INTRAMUSCULAR IMMUNOGLOBULIN

6. MARKET BY APPLICATION

6.1. HYPOGAMMA GLOBULINEMIA
6.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
6.3. PRIMARY IMMUNODEFICIENCY DISEASES
6.4. MYASTHENIA GRAVIS
6.5. MULTIFOCAL MOTOR NEUROPATHY
6.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
6.7. INFLAMMATORY MYOPATHIES
6.8. SPECIFIC ANTIBODY DEFICIENCY
6.9. GUILLAIN-BARRE SYNDROME
6.10. OTHER APPLICATIONS

7. MARKET BY DISTRIBUTION CHANNEL

7.1. HOSPITAL PHARMACY
7.2. SPECIALTY PHARMACY
7.3. OTHER DISTRIBUTION CHANNELS

8. MARKET BY END-USER

8.1. HOSPITALS & CLINICS
8.2. HOMECARE

9. COMPETITIVE LANDSCAPE

9.1. KEY STRATEGIC DEVELOPMENTS
- 9.1.1. MERGERS & ACQUISITIONS
- 9.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 9.1.3. PARTNERSHIPS & AGREEMENTS
- 9.1.4. BUSINESS EXPANSIONS & DIVESTITURES
9.2. COMPANY PROFILES
- 9.2.1. ABL BIO
- 9.2.2. CELLTRION
- 9.2.3. GREEN CROSS
- 9.2.4. ORUM

Product Code: 46405

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IMMUNOGLOBULIN
TABLE 2: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 3: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 4: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 5: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 6: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 7: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 8: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 9: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 10: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)
TABLE 11: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2028 (IN $ MILLION)
TABLE 12: LIST OF MERGERS & ACQUISITIONS
TABLE 13: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 14: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 15: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: OPPORTUNITY MATRIX
FIGURE 4: KEY BUYING CRITERIA
FIGURE 5: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021
FIGURE 6: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 7: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 8: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 9: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 10: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 11: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021
FIGURE 12: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)
FIGURE 13: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)
FIGURE 14: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2028 (IN $ MILLION)
FIGURE 15: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021
FIGURE 16: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 17: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 19: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 20: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 21: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)
FIGURE 22: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 23: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)
FIGURE 24: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 25: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 26: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021
FIGURE 27: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: SOUTH KOREA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021
FIGURE 31: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 32: SOUTH KOREA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)